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Abstract:  Muscular  dystrophies  are  a  group  of  diseases  that  primarily  affect  striated 
muscle  and  are  characterized  by  the  progressive  loss  of  muscle  strength  and  integrity. 
Major forms of muscular dystrophies are caused by the abnormalities of the dystrophin 
glycoprotein complex (DGC) that plays crucial roles as a structural unit and scaffolds for 
signaling molecules at the sarcolemma. α-Dystrobrevin is a component of the DGC and 
directly associates with dystrophin. α-Dystrobrevin also binds to intermediate filaments as 
well  as  syntrophin,  a  modular  adaptor  protein  thought  to  be  involved  in  signaling. 
Although  no  muscular  dystrophy  has  been  associated  within  mutations  of  the  
α-dystrobrevin gene, emerging findings suggest potential significance of α-dystrobrevin in 
striated muscle. This review addresses the functional role of α-dystrobrevin in muscle as 
well as its possible implication for muscular dystrophy. 
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1. Introduction 
α-Dystrobrevin  is  a member of the dystrophin gene family with  homology to  the cysteine-rich 
carboxy-terminal  domain  of  dystrophin  [1,2].  α-Dystrobrevin  was  identified  as  human  and  mouse 
homologues  of  an  87  kDa  phosphoprotein  found  at  the  Torpedo  electric  organ  post-synaptic 
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membrane [1,3,4].  In  striated  muscle,  dystrobrevin  and  dystrophin  are  both  localized  to  the 
cytoplasmic face of the sarcolemma, and form a macromolecular complex with a variety of proteins 
and glycoproteins, termed dystrophin-glycoprotein complex (DGC) [5]. The DGC plays crucial roles 
in  maintaining  the  structural  integrity  of  muscle  fibers  by  linking  the  extracellular  matrix  to  the 
subsarcolemmal cytoskeleton, and also provides a scaffold for signaling molecules. The abnormalities 
of the DGC are recognized to be responsible for several forms of progressive muscular dystrophies. 
The  absence  of  dystrophin  results  in  loss  of  the  entire  DGC  from  the  sarcolemma  and  leads  to 
Duchenne muscular dystrophy (DMD) [6]. Mutations in sarcoglycan genes, one of the components of 
the DGC, result in several types of limb-girdle muscular dystrophy (sarcoglycan-deficient LGMD or 
SD-LGMD).  Although  α-dystrobrevin  directly  associates  with  dystrophin  and  sarcoglycan 
complex [7,8],  no mutation  has  been  identified  in  muscular  dystrophy  patients  hitherto.  However,  
α-dystrobrevin knockout mice, which demonstrate mild myopathy, have provided clues of its potential 
functions  in  striated  muscle  [9].  Recently,  α-dystrobrevin  is  known  to  be  subject  to  extensive 
alternative  splicing  [4,10],  which  results  in  changes  in  its  subcellular  distribution  and  function  in 
muscle [11]. Furthermore, a number of binding partner of dystrobrevin have been identified. In this 
review,  we  focus  on  the  recent  findings  regarding  the  alternative  splicing  of  α-dystrobrevin,  its 
interactions with other proteins, and implications for muscular dystrophy.  
2. α-Dystrobrevin Gene and Transcripts 
The  mammalian  dystrobrevin  protein  family  is  comprised  of  α-  and  β-dystrobrevin  which  are 
encoded by the DTNA and DTNB gene, respectively [4,12]. α-Dystrobrevin is expressed predominantly 
in muscle and brain whereas β-dystrobrevin is expressed in non-muscle tissues [3,4,12]. The human  
α-dystrobrevin gene consists of 23 coding exons [10].  
α-Dystrobrevin is known to be subject to extensive splicing regulation. The alternative usage of 
three  exons—21,  17B,  and  11B—generates  transcripts  of  different  lengths  encoding  three  major  
α-dystrobrevin  isoforms  in  human  skeletal  muscle:  α-dystrobrevin  1,  α-dystrobrevin  2,  and  
α-dystrobrevin 3 [10] (Figure 1). Additional diversity is observed due to alternative splicing within the 
coding regions referred to as variable regions 1, 2 and 3 [4]. Firstly, variable region 1 (vr1) consists of 
a short exon encoding three amino acids (exon 9). In mouse, the transcripts including this exon are 
primarily restricted to brain [4,13], but are present in brain, heart, and skeletal muscle in human [10]. 
Variable region 2 (vr2) consists of exons 17A and 17B. Exon 17B encodes the unique C-terminal tail 
of α-dystrobrevin 2. The first 21 nucleotides of exon 17B are also  found in the α-dystrobrevin 1 
transcript as a result of splicing at a cryptic site [14]. In mouse, the expression of the vr2 region in the  
α-dystrobrevin 1 transcript appears to be developmentally regulated [13]. Lastly, variable region 3 
(vr3)  consists  of  exons  11A,  11B  and  12.  Exon  11B  encodes  the  unique  C-terminal  tail  of  
α-dystrobrevin  3.  In  α-dystrobrevin  1  and  α-dystrobrevin  2,  four  in-frame  alternatively  spliced 
transcripts, may arise by joining exon 10 with either exon 11A, 12 or 13, or by joining exon 11A with 
either 12 or 13 (i.e., 10-11A-13, 10-12-13, 10-13, 10-11A-12-13) [10]. In mouse skeletal muscle, the 
splicing of vr3 has also been reported to be developmentally controlled [13,15,16]. Previous analyses 
of  mouse  myoblast  cultures  demonstrated  a  transition  from  α-dystrobrevin  lacking  vr3  (Δvr3)  to  
α-dystrobrevin including vr3 (+vr3) during differentiation. We also showed that the frequency of vr3 Int. J. Mol. Sci. 2011, 12                       
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inclusion  increases  in  skeletal  muscle  tissue  during  normal  postnatal  development  of  mice  [17]. 
However, we found that α-dystrobrevin Δvr3, which should be the fetal isoform in mouse, is expressed 
exclusively in adult human muscle, and the relative amount of α-dystrobrevin +vr3 is higher in human 
fetal, than in adult, cardiac muscle [17]. These results suggest a different, or possibly an opposite, 
mode  of  regulation  of  vr3  alternative  splicing  between  human  and  mouse.  Since  this  portion,  as 
described below, corresponds to one of syntrophin binding sites, these results might imply a functional 
difference of α-dystrobrevin between mice and human. Recently, Bohm et al. extensively analyzed the 
differences in α-dystrobrevin splicing between human and mouse [18]. They also showed the opposite 
mode of vr3 splicing regulation  between human and mouse (exon 12 and 13  by their numbering 
method). In addition, they found another novel exon just upstream of the vr3. The exon is alternatively 
spliced in human but not in mice, and suggested to contain another syntrophin binding motif, although 
the transcripts containing this exon are less expressed in skeletal muscle.  
Figure 1. Alternative splicing of human α-dystrobrevin. Exons represented as thick boxes 
are  translated  segments  and  thin  boxes  indicate  untranslated  segments.  The  exon 
numbering is based on [10], which is different from that proposed by [18]. Introns and 
downstream flanking regions are represented by horizontal lines. Gray boxes represent the 
alternatively spliced exons: variable regions 1 (vr1), 2 (vr2), and 3 (vr3). The different 
isoforms of protein are represented below. The identifiable domains are boxed: EF, EF 
hand region; ZZ, zinc-binding domain; CC, coiled-coil domain; Y, unique tyrosine kinase 
substrate domain. Suggested syntrophin binding sites (SBS) and dystrophin binding site 
(DBS) are indicated. This figure is a modified version of an illustration in [17]. 
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3. Structure of Dystrobrevin Protein and Localization in Striated Muscle 
α-Dystrobrevin  is  comprised  of  four  major  domains,  two  EF-hand  motifs  that  potentially  bind 
calcium, a ZZ-domain, an α-helical coiled-coil domain containing a dystrophin binding site, and a 
tyrosine  kinase  substrate  domain  (Figure  1)  [7].  α-Dystrobrevin  1,  α-dystrobrevin  2  and  
α-dystrobrevin 3 bind to the sarcoglycan complex via the N-terminal region [8]. α-Dystrobrevin 1 and 
α-dystrobrevin 2 bind dystrophin through the highly conserved coiled-coil domain [2,7]. α-Dystrobrevin 1 
and α-dystrobrevin 2 have syntrophin binding sites at the upstream of the coiled-coil domain [19].  
α-Dystrobrevin  1,  which  has  a  unique  C-terminal  tyrosine  kinase  substrate  domain  [1,4],  is 
localized in the sarcolemma and is abundant at the neuromuscular junction (NMJ), especially in the 
crest  of  the  junctional  folds  [11,14,15,20].  α-Dystrobrevin  2  is  localized  around  the  entire 
circumference of the sarcolemmal membrane including the NMJ, and concentrated in the troughs of 
the folds [11]. α-Dystrobrevin 2 co-localizes with only dystrophin at the NMJ, while α-dystrobrevin 1  
co-localizes with both dystrophin as well as utrophin which shares structural and functional similarities 
with dystrophin [11]. α-Dystrobrevin 3, which lacks both syntrophin and dystrophin binding sites, is 
capable of binding to the sarcoglycan complex via the N-terminal region [8]. α-Dystrobrevin 3 has 
been suggested to be localized in the cytoplasm [21].  
4. The Role of Dystrobrevin for Structural Integrity of Muscle—Interaction with Cytoskeletal 
Binding Partners 
α-Dystrobrevin  is  a  component  of  DGC,  which  is  indispensable  for  the  structural  integrity  of 
muscle. As mentioned above, it directly associates with dystrophin at its coiled-coil domain and with 
sarcoglycan  complex  in  its  N-terminal  half.  As  is  the  case  with  dystrophin,  α-dystrobrevin  may 
also function  as  a  structural  scaffold  linking  the  DGC  to  the  intracellular  cytoskeleton.  By  using 
the yeast two-hybrid  and  co-immunoprecipitation  analysis,  several  groups  identified  additional  
α-dystrobrevin-binding proteins: syncoilin, β-synemin, and dysbindin [22–24] (Figure 2). Syncoilin 
and β-synemin are both intermediate filament (IF) proteins. The IFs play a structural role by forming 
an  important  part of the cell cytoskeleton  and providing mechanical  stability to  the cells  [25]. In 
muscle cells, the IFs encircle the Z-lines of each integral myofibril, thereby connecting all adjacent 
myofibrils and linking the Z-lines of the peripheral layer of cellular myofibrils to the sarcolemma [26].  
Syncoilin is highly expressed in striated muscle, and co-localizes with α-dystrobrevin at the NMJ 
and sarcolemma. Syncoilin interacts with α-dystrobrevin via vr3 and its flanking region [22]. Syncoilin 
also binds to desmin, a muscle-specific intermediate filament protein, and has been thought to organize 
desmin  filaments  to  the  Z-line  [27].  The  α-dystrobrevin/syncoilin  interaction  provides  a  further 
physical linkage between the DGC and the cytoskeleton, in addition to the well-characterized linkage 
between  dystrophin  and  actin.  Interestingly,  syncoilin-null  mice  show  a  reduced  force-generating 
capacity,  suggesting  that  the  link  with  syncoilin  may  be  important  for  force  transduction  during 
contraction, although the DGC is still intact without syncoilin [28]. In addition, the increased syncoilin 
immunolabeling  was  reported  in  the  sarcolemma  of  immature  regenerating  fibers  in  patients  with 
Duchene  muscular  dystrophy  [29]  and  mouse  models  of  muscle  disease  [22].  This  suggests  that Int. J. Mol. Sci. 2011, 12                       
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syncoilin and its binding partner, α-dystrobrevin +vr3, may be required for muscle regeneration in 
response to injury.  
Figure  2.  Schematic  illustration  of  the  dystrophin-glycoprotein  complex  network  in 
muscle. α-Dystrobrevin (α-DB) forms a core part of the DGC with dystrophin, syntrophin,  
α-dystroglycan  (α-DG),  β-dystroglycan  (β-DG),  sarcoglycan  complex  (SGC),  and 
sarcospan (SPN). Proteins involved in structural integrity and signaling are highlighted in 
purple and red, respectively.  
 
 
β-Synemin is a large, heteropolymeric IF protein that forms IFs with other major IF proteins, such 
as  desmin  [23].  β-Synemin  interacts  and  co-localizes  with  α-dystrobrevin  at  the  NMJ  and 
myotendinous  junction  (MTJ)  [23,30].  The  α-dystrobrevin/β-synemin  interaction  provides  another 
connection between the IF networks and the DGC. Furthermore, β-synemin interacts with plectin, a 
linker protein of IFs to Z-discs [31]. Interestingly, plectin is also suggested to interact directly with  
α-dystrobrevin.  Taken  together,  these  interactions  between  α-dystrobrevin  and  IF  proteins  would 
stabilize the sarcolemma and protect it against contraction-imposed stress by tethering IFs to the DGC 
at the sarcolemma (Figure 2). 
Dysbindin is a ubiquitously expressed coiled-coil-containing protein, although the expression in 
muscle is relatively low [24]. In skeletal muscle, dysbindin is located at the sarcolemma. Dysbindin 
binds  to  α-dystrobrevin  through  coiled-coil  domains  and  interact  with  myospryn  [24,32].  Lastly, 
myospryn  is  a  muscle-specific  protein,  localized  to  the  sarcolemmal  region  of  skeletal  muscle. 
Myospryn  is  suggested  to  function  as  a  docking  platform  for  additional  structural  proteins  and 
signaling molecules, such as α-actinin 2 and protein kinase A, respectively [33,34]. 
5. The Role of Dystrobrevin in Signaling—Interaction with Syntrophin 
α-Dystrobrevin 1 and α-dystrobrevin 2 bind directly with syntrophin, which is a modular adaptor 
protein  thought  to  be  involved  in  signaling  [35–38]  (Figure  2).  Skeletal  muscle  contains  several 
isoforms—α-, β1-, β2-, and γ2-syntrophin—encoded by different genes [38–42]. α-Syntrophin is the Int. J. Mol. Sci. 2011, 12                       
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major isoform in skeletal and cardiac muscles [36,38,41], being expressed in the sarcolemma and 
NMJ [14,20].  β1-Syntrophin  also  localizes  at  the  sarcolemma  and  NMJ,  whereas  β2-  and  
γ2-syntrophin are largely confined to the NMJ. With regard to the syntrophin binding site on Torpedo 
87K protein, a homologue of human α-dystrobrevin 1, Dwyer et al. mapped the α-syntrophin binding 
site to a region analogous to exons 12–13 of human α-dystrobrevin [37], and Ahn et al. reported a  
β1-syntrophin binding site in a region corresponding to exons 13–14 of human α-dystrobrevin [36]. 
From  yeast two-hybrid  study, Newey  et al. identified another binding site situated within the vr3 
region in mouse, and suggested that α-dystrobrevin contains two independent syntrophin binding sites 
in tandem [43]. Recently, we directly confirmed that α-syntrophin interacts with α-dystrobrevin via the 
vr3 domain in human muscle and revealed dramatic decrease in binding between α-syntrophin and  
α-dystrobrevin mutant in vr3 [17]. α-Syntrophin knockout mice exhibit marked hypertrophy during 
muscle regeneration and deranged NMJ accompanied by impaired ability to exercise, suggesting a role 
of α-syntrophin in the regulation of muscle volume and formation of highly organized NMJ [44,45]. 
Syntrophin  has  the  potential  to  co-ordinate  the assembly  of  several  important  proteins  such  as 
neuronal nitric oxide synthase (nNOS)  [46], stress-activated protein kinase-3 [47], Grb2 [48], and 
calmodulin [49,50] to the DGC. nNOS generates NO from L-arginine in many different cells. nNOS at 
the  sarcolemma  regulates  local  blood  flow  in  contracting  skeletal  muscle  in  part  by  antagonizing 
sympathetic  vasoconstriction  [51].  The  expression  of  nNOS  is  decreased  in  many  muscular 
dystrophies, resulting in decreased vasodilation  [52]. Consistent with nNOS being associated with  
α-syntrophin in muscle, α-syntrophin knockout mice lack sarcolemmal nNOS [53]. It is also reported 
that normalized production of NO protects dystrophin-deficient mdx muscle from degeneration [54]. 
Recently,  transient  receptor  potential  channels  (TRPCs)  were  also  found  to  associate  with  
α-syntrophin [55]. These channels anchored to the DGC are suggested to form a signaling complex 
that  modulates  cation  entry  and  regulates  calcium  homeostasis  in  skeletal  muscles  [56].  Calcium 
homeostasis and calcium-dependent signaling pathways play an important role in regulating muscle 
contractility,  metabolism,  and  gene  expression  [57].  Thus,  these  signaling  pathways  via  α-
dystrobrevin/syntrophin may have a significant impact on muscle function. 
Very recently, α-catulin, a catenin/vinculin-related molecule, was identified as a binding partner of 
α-dystrobrevin 1 [58]. α-Catulin, which co-localizes with α-dystrobrevin at nerve bundles and blood 
vessels, is thought to regulate α1D-adrenergic receptor signal transduction. It was shown that α-catulin 
interact with α-dystrobrevin 1 at its C-terminal domain. Since α-catulin is ubiquitously expressed, 
including  in  skeletal  muscle  [59],  the  interaction  between  α-dystrobrevin  and  α-catulin  may  be 
involved in some forms of receptor-mediated signaling in skeletal muscle. 
6. Dystrobrevin in Muscle Disease 
Despite  the  evidence  that  abnormalities  of  the  DGC  components  cause  various  muscular 
dystrophies, so far no mutation in α-dystrobrevin has been reported in muscular dystrophy patients. 
However, a missense mutation was found in a four-generation Japanese family with left ventricular 
non-compaction (LVNC) [60], a cardiomyopathy, often associated with neuromuscular disorders [61]. 
LVNC  is  characterized  by  a  pattern  of  prominent  trabecular  meshwork  and  deep  inter-trabecular 
recesses, and is thought to be caused by arrest of normal endomyocardial morphogenesis [62].  Int. J. Mol. Sci. 2011, 12                       
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Histological analysis showed that the level of α-dystrobrevin is greatly reduced at the sarcolemma 
of patients with DMD and SD-LGMD, suggesting that dystrophin and sarcoglycan are required for 
anchorage of α-dystrobrevin at the sarcolemma [21]. On the other hand, Jones et al. analyzed the 
expression of α-dystrobrevin by immunohistochemistry in biopsies from 162 patients with myopathies 
of unknown etiology with normal staining for dystrophin and other dystrophin-associated proteins [14]. 
Among the patients, deficiency of α-dystrobrevin was found in 16 patients, while no mutation was 
identified in the coding region of the α-dystrobrevin gene. Although there was a significant variety in 
severity  and  age  of  onset,  all  patients  presented  with  congenital-onset  hypotonia  and  weakness, 
indicating a new disease entity caused by α-dystrobrevin deficiency.  
In addition, mice lacking α-dystrobrevin exhibit skeletal and cardiac myopathies, defects of NMJ 
maturation, and abnormal  myotendinous  junctions [9,63,64]. At NMJs in  α-dystrobrevin  knockout 
mice, the distribution of acetylcholine receptor (AChR) becomes granular in appearance with ragged 
edges. Myotube cultures from α-dystrobrevin knockout mice forms normal AChR clusters; however, 
these clusters quickly disappear into micro-aggregates, suggesting that α-dystrobrevin is not required 
for initial formation of the postsynaptic apparatus at the NMJ, but indispensable for its maturation and 
stabilization. Despite the presence of a structurally intact DGC in the sarcolemma, these mice show a 
striking  displacement  of  nNOS  from  the  sarcolemma  and  impaired  NO-mediated  signaling  [9]. 
Moreover,  the  biochemical  association  between  dystrophin  and  β-dystroglycan  is  impaired  in  
α-dystrobrevin knockout mice, suggesting a role for α-dystrobrevin in stabilizing the DGC [65].  
Furthermore,  we  revealed  mis-regulated  alternative  splicing  of  α-dystrobrevin  in  muscle  from 
myotonic  dystrophy  type  1  (DM1)  patients  [17].  DM1  is  proposed  as  a  ―spliceopathy‖,  i.e.,  a  
trans-effect  on  the  alternative  splicing  of  many  RNAs,  leading  to  inappropriate  expression  of 
aberrantly  spliced  products,  such  as  Cl  channel,  ryanodine  receptor  and  dystrophin  [66–69].  
α-Dystrobrevin mRNA including vr3 is increased in both skeletal and cardiac muscle of DM1 patients. 
Interestingly,  the  splicing  abnormality  is  correlated  with  the  muscular  disability  of  DM1.  The 
aberrantly spliced α-dystrobrevin isoform has an increased binding capacity for α-syntrophin, thereby 
recruiting excess α-syntrophin to the sarcolemma in DM1 muscle.  
7. Concluding Remarks 
A  number  of  proteins  that  comprise  the  link  between  striated  muscle  Z-disc  and  peripheral 
structures,  such  as  the  costamere,  have  been  discovered.  Recent  studies  suggest  that  this  protein 
network acts as a structural and signaling center for striated muscle to ensure coordinated contractile 
activity. The importance of the network to normal muscle function has emerged from investigations 
into the causes of muscular dystrophies and cardiomyopathies. One of the key players in the network is 
α-dystrobrevin  that  mediates  signaling  and  structural  function  of  the  DGC.  Although  functional 
differences among the various splicing variants and detailed roles of their counterparts still remain 
unknown, future studies will shed much more light on the importance of α-dystrobrevin in striated 
muscle and implications for muscular dystrophy. Int. J. Mol. Sci. 2011, 12                       
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